NCT03798912 (RaniPill) is a Phase 1 clinical trial of RaniPill capsule containing octreotide in Healthy Volunteers, sponsored by RANI Therapeutics.

Who is sponsoring NCT03798912?

NCT03798912 is sponsored by RANI Therapeutics.

What drugs are being tested in NCT03798912?

Interventions in NCT03798912: RaniPill capsule containing octreotide.

What condition does NCT03798912 study?

NCT03798912 studies Healthy Volunteers.

Is NCT03798912 still recruiting?

NCT03798912 is currently completed. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT03798912: RaniPill

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform

Completed Phase 1 Last updated 8 October 2020

What this trial tests

Phase 1 trial testing RaniPill capsule containing octreotide in Healthy Volunteers in 62 participants. Completed in 17 February 2020.

Timeline

9 July 2019

Primary endpoint
17 February 2020

17 February 2020

Quick facts

Lead sponsor	RANI Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	62
Start date	9 July 2019
Primary completion	17 February 2020
Estimated completion	17 February 2020
Sites	1 location across Australia

Drugs / interventions tested

RaniPill capsule containing octreotide

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

RANI Therapeutics

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to ascertain the safety, tolerability and performance of the RaniPill capsule in healthy volunteers

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Foundations of gastrointestinal-based drug delivery and future developments.
Chu JN, Traverso G. · · 2022 · cited 136× · PMID 34785786 · DOI 10.1038/s41575-021-00539-w
Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.
Pechenov S, Revell J, Will S, Naylor J, et al · · 2021 · cited 56× · PMID 34795324 · DOI 10.1038/s41598-021-01750-0
Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.
Coffey JW, Gaiha GD, Traverso G. · · 2021 · cited 41× · PMID 32466690 · DOI 10.1146/annurev-pharmtox-030320-092348
Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances.
Baral KC, Choi KY. · · 2025 · cited 39× · PMID 40284395 · DOI 10.3390/pharmaceutics17040397

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other RANI Therapeutics trials

Trials by the same sponsor.

NCT06891287 — An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. · Phase 1 · recruiting
NCT05890118 — Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule · Phase 1 · completed
NCT05164614 — Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule · Phase 1 · completed
NCT04911296 — Pill Swallow Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03798912 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RANI Therapeutics
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03798912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing